Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: November 14, 2014
Event: Settlement of patent litigation with Syntrix Biosystems, Inc.
Key Financial Metrics
This filing does not report standard operating metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the specific legal settlement:
- Accrued Liability (as of Sept 28, 2014): $149 million for past damages.
- Settlement Payment: $70 million one-time payment to Syntrix.
- Net Financial Impact: Reduction of accrued liability by $79 million ($149 million accrued minus $70 million paid).
Material Changes
The primary material change is the resolution of pending patent litigation in the United States District Court for the Western District of Washington (pending appeal in the Federal Circuit). The Company agreed to a stipulated motion to dismiss the litigation with prejudice and to vacate the judgment against the Company. No admission of liability was made by either party.
Outlook, Risks, and Unusual Items
Unusual Item: The settlement involves a significant one-time cash outflow of $70 million. In exchange, Illumina received a release of past damages and a fully paid-up exclusive license to U.S. Patent No. 6,951,682.
Risk Mitigation: The settlement eliminates the uncertainty of the ongoing appeal and the potential for higher damages, as the accrued amount of $149 million was significantly higher than the settlement payment.
Investor Verification Checklist
- Verify the impact of the $70 million cash outflow on the Company's current quarter liquidity and cash flow statement.
- Confirm the accounting treatment of the $79 million reduction in accrued liabilities in the upcoming financial statements.
- Assess the strategic value of the exclusive license to U.S. Patent No. 6,951,682 for future product development or market protection.
- Review the Company's disclosure of any remaining legal contingencies not covered by this settlement.